SANTHERA N | 0.6400 / 0.00% |
Date/Time | 03/28 / 17:30 |
Chg. / Chg.(%) | 0.0000 / 0.00% |
Bid | 0.6200 / 5551 |
Ask | 0.6840 / 6944 |
Open | 0.6400 |
Previous Close | 0.6400 |
High | 0.6770 |
Low | 0.6160 |
Volume [CHF] | 95,132.4160 |
Volume [Units] | 149,745 |
Price fixings | 88 |
ISIN | CH0027148649 |
Security | SANN |
Exchange | SIX Swiss Exchange |
Type | Stock |
Exchange | Last | Volume | |
---|---|---|---|
SIX Swiss Ex.. | 0.6400 | ![]() |
149,745 |
Cboe Europe .. | 0.64 | ![]() |
10,896 |
London Domes.. | 0.6400 | ![]() |
7,330 |
Cboe Europe .. | 0.64 | ![]() |
5,714 |
Turquoise | 0.63 | ![]() |
2,859 |
Lang & Schwa.. | 0.61 | ![]() |
|
Nasdaq Other.. | 1.2000 | 120 | |
München | 13.700 | 0 | |
Berlin | 13.720 | 0 | |
Frankfurt | 13.6400 | 0 | |
TradeGate | 13.76 | 0 |
News
- Santhera and ReveraGen Start Rolling NDA Submission to the FDA for Vamorolone for the Treatment of Duchenne Muscular Dystrophy
03/29/2022 / 07:00 - GlobeNewswire - Santhera and ReveraGen to Present Efficacy and Safety Data with Vamorolone at 2022 Muscular Dystrophy Association Conference
03/15/2022 / 07:05 - GlobeNewswire - Santhera Completes Ordinary Capital Increase to Create Treasury Shares for Future Financing
03/15/2022 / 07:00 - GlobeNewswire - Santhera Announces Preliminary 2021 Financial Results and Increases Issued Share Capital to Create Treasury Shares for Future Financing
03/11/2022 / 07:00 - GlobeNewswire - Santhera Signs Gene Therapy Agreement with SEAL Therapeutics
02/28/2022 / 07:00 - GlobeNewswire